Taiho Ventures, LLC, the corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., marks its 10th anniversary since establishment in 2016, underscoring a decade of strategic investments in therapeutics startups and healthcare technologies.
Over the past decade, Taiho Ventures has emerged as a significant player in the Japanese pharmaceutical industry's corporate venture capital landscape, maintaining the largest fund size among its peers. The firm has focused on leveraging its research, development, and business management expertise to deliver cutting-edge technologies and therapies to society.
Since its inception, Taiho Ventures has invested in over 30 innovative companies, contributing to the development of novel therapeutics and healthcare technologies worldwide. The firm has achieved multiple successful exits, including high-profile acquisitions such as Dren Bio by Sanofi, Halda Therapeutics by Johnson & Johnson, and Orna Therapeutics by Eli Lilly and Company. Additionally, several of its portfolio companies have reached initial public offering status.
The company's collaboration with Arcus Biosciences, Inc., one of its earliest investments, has resulted in exclusive licenses granted to Taiho Pharmaceutical for five pipeline programs in select territories, thereby enhancing its research and development pipeline.
Taiho Ventures maintains an active investment presence across the United States, Europe, and Japan, allowing it to identify and support promising startups on a global scale. Its evergreen fund structure supports a patient, long-term investment strategy, providing continuity for portfolio companies and reducing financial pressure.
As it enters its second decade, Taiho Ventures remains committed to fostering long-term value through collaboration with entrepreneurs and innovators, aiming to develop transformative healthcare technologies that address unmet medical needs.